🚀 Medial Secures Investment on Shark Tank India - Fueling the Future of Professional Social Networking. 🔥
Login

News on Medial

Redcliffe Labs posts Rs 419 Cr revenue in FY25; narrows EBITDA losses

EntrackrEntrackr · 6m ago
Redcliffe Labs posts Rs 419 Cr revenue in FY25; narrows EBITDA losses
Medial

Redcliffe Labs posts Rs 419 Cr revenue in FY25; narrows EBITDA losses Diagnostics platform Redcliffe Labs has posted a 20% increase in its operating revenue to Rs 419 crore in FY25 from Rs 350 crore in FY24 and managed to narrow its EBITDA losses, as per the company’s press release. Diagnostics platform Redcliffe Labs has posted a 20% increase in its operating revenue to Rs 419 crore in FY25 from Rs 350 crore in FY24, as per the company’s press release. The Gurugram-based firm also managed to reduce its EBITDA losses from -38% to -21% during the same period. Founded by Aditya Kandoi, Redcliffe operates a nationwide network of over 80 labs and claims to have the widest home sample collection footprint in the country. Diagnostic services contributed over 95% of the company’s revenue in FY25, with the rest coming from product sales and other operating income. The company said it diagnosed over 2.5 million cases last fiscal and continues to focus on expanding in underserved regions, with more than 70% of its testing volumes now coming from Tier II cities and beyond. On the profitability front, Redcliffe reported a gross margin of 70% in FY25 and is aiming to expand it to 74% in FY26. It has also set a revenue target of Rs 560 crore for the ongoing fiscal through organic growth and strategic acquisitions. “We are transforming lives and making diagnostics a first-line solution for millions who were previously underserved,” said Kandoi. The company plans to expand its presence to over 300 cities with 150 labs by FY28. According to startup data platform TheKredible, Redcliffe has raised $113 million to date, including a $42 million Series C round led by LeapFrog. It also acquired Bengaluru-based Celara Diagnostics in a $7 million deal. Redcliffe competes with players like PharmEasy-owned Thyrocare, Tata 1mg, and Healthians.

1

Related News

Redcliffe Labs crosses Rs 350 Cr revenue in FY24, narrows losses significantly

EntrackrEntrackr · 1y ago
Redcliffe Labs crosses Rs 350 Cr revenue in FY24, narrows losses significantly
Medial

Online diagnostic platform Redcliffe, backed by Leapfrog Investments, reported modest growth during the fiscal year ending March 2024, achieving a 28% reduction in losses, largely attributed to a significant cut in advertising and material costs. Redcliffe’s revenue from operations grew by 11% to Rs 348.38 crore in FY24 from Rs 313.86 crore in FY23, as per its consolidated financial statements sourced from the Registrar of Companies (RoC). Redcliffe Labs operates a network of laboratories specializing in pathological testing across various branches of biochemistry and radiology. Around 98% of its operating revenue came from these services, contributing Rs 341.02 crore in FY24. The sale of products and other operating income accounted for Rs 2.16 crore and Rs 5.20 crore, respectively, during the last fiscal year. The company’s total income crossed Rs 353 crore in FY24 with other non-operating income worth Rs 5.3 crore including interest income and excess provisions written back. The Noida-based company’s advertising costs fell by 45% to Rs 65.38 crore, and material costs, which declined by 15% to Rs 106.31 crore in FY24. However, there was a notable increase in laboratory test charges and depreciation costs which grew by 62.2% and 3X respectively. Overall, the company successfully controlled its total expenses, which dropped 14% to Rs 556.16 crore in FY24 from Rs 647.30 crore in FY23. In the end, the company managed to decrease its losses by 28% to Rs 250 crore in FY24 from Rs 345 crore in FY23. Its ROCE and EBITDA margin stood at -544.68% and -57.55%, respectively. On a unit basis, Redcliffe Labs spent Rs 1.6 to earn a rupee in FY24. Redcliffe recorded cash and bank balances of Rs 15.87 crore and had current assets worth Rs 89.64 crore as of FY24. According to TheKredible, Redcliffe Labs has amassed total funding of $113 million to date, including investments from LeapFrog. The company recently secured $42 million in a Series C funding round and acquired Bengaluru-based Celara Diagnostics for approximately $7 million. Entrackr exclusively reported the development. Among venture-funded companies, Redcliffe competes with PharmEasy-owned Thyrocare, Healthians, and 1mg. Tata 1mg’s revenue from operations increased to Rs 1,968 crore in FY24 from Rs 1,627 crore in FY23 while Healthians achieved EBITDA profitability with Rs 243 crore revenue in FY24. Thyrocare, which is a public company, reported 20% jump in revenue to Rs 177.4 crore in Q2 FY25 with a profit after tax of Rs 26.4 crore. While founded in 2018, Redcliffe Labs saw real interest, and backing for its plans in the year after Covid struck, when diagnostic labs were considered as good as money printing machines by some investors. That has meant the usual spike in funding, followed by the struggle we are seeing in the past two years, as momentum has all but died out, and much like edtech, the legacy players including hospitals have fought back to reclaim their space. On a smaller base as compared to its peers, Redcliffe’s topline growth remains unimpressive, and the bottomline pressure will continue to hurt. While it has done its own share of acquisitions to buy its way out of stagnation, that has clearly not worked, to no one’s surprise. The whole category faces a challenge of growth today, even if the overall size is much much larger than pre-2020, and looks set to remain that way. The only issue is the scramble for share among many more players, including those who raised money at hefty post-covid valuations, making growth difficult. Despite many promises, no firm has stood out for a breakthrough offering like faster speed, lower costs or specialised accurate diagnosis, to stand out. Fy25 promises to be yet another year of attrition, and for Redcliffe, the best hope might yet remain a respectable acquisition by a larger player, than trying to cut its own pathway ahead.

Medibuddy posts Rs 725 Cr revenue in FY25, narrows losses by 37%

EntrackrEntrackr · 25d ago
Medibuddy posts Rs 725 Cr revenue in FY25, narrows losses by 37%
Medial

MediBuddy posts Rs 725 Cr revenue in FY25, narrows losses by 37% Following more than 2X growth in the fiscal year ending March 2024, digital healthcare platform MediBuddy reported modest growth in its operating scale in FY25, while managing to narrow its losses by 37% during the period. MediBuddy's operating revenue grew 12.3% year-on-year to Rs 724.6 crore in FY25 from Rs 645.4 crore in the previous fiscal year (FY24), according to the company's annual financial statements filed with the Registrar of Companies (RoC). MediBuddy, a digital healthcare platform, provides online and offline medical consultations, medicine delivery, lab tests, surgeries, and insurance services, with revenue from these forming the primary source of income at Rs 722 crore, supplemented by Rs 2.5 crore from other operating sources. The company also earned Rs 18.42 crore from non-operating sources, including interest on fixed deposits and current investments, written-off liabilities, and other miscellaneous income, pushing its total income to Rs 743 crore in FY25. On expenses, the cost of materials was the largest at 38% of total expenses, standing at Rs 333 crore. Employee benefits expenses rose marginally by 8% to Rs 176.8 crore, including Rs 6 crore in ESOP expenses. Sales payout expenses, including commissions to selling agents, fell 7% to Rs 155.47 crore. The company spent Rs 42.5 crore on safety and security and Rs 32.5 crore on IT. Other overheads, including legal and professional fees, advertising, depreciation and amortization, and finance costs, amounted to Rs 138.7 crore. Overall expenses for the Bengaluru-based firm remained flat at Rs 879 crore, with controlled expenditure and a 12% rise in revenue helping to narrow losses by 37% to Rs 137 crore from Rs 215.7 crore in FY24. On a unit basis, MediBuddy spent Rs 1.21 to earn one rupee of operating revenue, with its EBITDA margin improving to -14.19% in FY25 from -25.67% in the previous year, resulting in an EBITDA loss of Rs 103 crore. As of March 2024, MediBuddy's current assets were Rs 395.2 crore, including cash and bank balances of Rs 80 crore. MediBuddy has raised over $190 million to date, last raising $18 million in August 2023 from existing investors Quadria Capital, Lightrock, and TEAMFund. It competes with companies including Pristyn Care-owned Lybrate, Practo, and mFine Tata 1mg.

Paper Boat posts Rs 668 Cr revenue in FY25; narrows losses by 24%

EntrackrEntrackr · 3m ago
Paper Boat posts Rs 668 Cr revenue in FY25; narrows losses by 24%
Medial

Paper Boat posts Rs 668 Cr revenue in FY25; narrows losses by 24% Hector Beverages Pvt Ltd, maker of Paper Boat drinks, saw steady growth in FY25, with a 16% year-on-year rise in operating scale and a 24% reduction in losses to under Rs 50 crore. Hector Beverages Pvt Ltd, maker of Paper Boat drinks, pursued steady growth in the fiscal year ending March 2025. The company recorded a modest 16% year-on-year increase in operating scale in the last fiscal year, while narrowing its losses by 24% to below Rs 50 crore. Paper Boat’s operating revenue rose to Rs 668.28 crore in FY25 from Rs 574.48 crore in FY24, its financial statements sourced from the Registrar of Companies (RoC) shows. Founded by former Coca-Cola executives Neeraj Kakkar and Niraj Biyani, Paperboat offers packaged juices, coconut water, traditional Indian snacks, and dry fruits. Products traded through third-party manufacturers contributed 66% of its operating revenue. Collection from this spiked 45% to Rs 441.43 crore in FY25 from Rs 304.32 crore in FY24. In contrast, revenue from its own manufactured products, which made up 33.78% of the total, declined 16% to Rs 225.72 crore during the fiscal year. Paper Boat also earned a non-operating income of Rs 14.2 crore, mainly from interest on bank deposits, taking its total income to Rs 682.44 crore. On the expense side, the cost of materials remained the largest component, which accounted for 62% of total expenses at Rs 444 crore in FY25. Employee benefit expenses rose 32% to Rs 90.35 crore, while selling and distribution costs stood at Rs 58.47 crore, and depreciation, travel, and other overheads pushed overall expenses to Rs 716.53 crore. The Peak XV-backed company cut its losses by 24% to Rs 48.25 crore in FY25, with ROCE at -14% and EBITDA margin at -3.86%. On a unit basis, it spent Rs 1.07 to earn a rupee of operating revenue in FY25. As of March 2025, the company’s current assets stood at Rs 276.17 crore, including cash and bank balances of Rs 42.39 crore. According to startup data intelligence platform TheKredible, Paperboat has raised $143 million to date from investors including GIC, Peak XV, Sofina Ventures, and A91 Partners. GIC holds a 25% stake in the company, while Sofina and Peak XV each own over 18%.

FirstCry-parent posts Rs 2,172 Cr revenue in Q3 FY25, cuts losses by 70%

EntrackrEntrackr · 11m ago
FirstCry-parent posts Rs 2,172 Cr revenue in Q3 FY25, cuts losses by 70%
Medial

FirstCry-parent posts Rs 2,172 Cr revenue in Q3 FY25, cuts losses by 70% Brainbees Solutions, the parent company of kids-focused omnichannel retailer FirstCry, has released its Q3 FY25 today. The report highlights sound financial growth, with a 14.3% year-on-year growth in scale and controlled losses by 70%. FirstCry's revenue from operations grew to Rs 2,172 crore in Q3 FY25 from Rs 1,900 crore in Q3 FY24, its unaudited financial statements sourced from the National Stock Exchange (NSE) show. The sale of its products through offline stores and websites in India and the international market was the primary source of revenue, accounting for nearly 82% of total operating revenue, while its subsidiary, GlobalBees, contributed Rs 422 crore. The company also made Rs 44 crore from interest income which took its overall revenue to Rs 2,217 crore in Q3 FY25, compared to Rs 1,936 crore in Q3 FY24. For the omnichannel retailer, the cost of procurement of materials accounted for 66% of the overall expenditure which increased 17% year-on-year to Rs 1,451 crore in Q3 FY25 from Rs 1,239 crore in Q3 FY24. FirstCry’s employee benefits stood at Rs 177 crore in Q3 FY25 which includes Rs 28 crore as ESOP cost. The marketing, legal, rent, and technology were other overheads that pushed the overall expenditure to Rs 2,210 crore in Q3 FY25 from Rs 1,978 crore in Q3 FY24. The decent scale and controlled expenditure helped FirstCry to reduce its losses by 70% to Rs 15 crore in the last quarter. Notably, the company reported a positive EBITDA of Rs 152 crore. As of the last trading session, FirstCry’s share price stood at Rs 419 per share, with a total market capitalization of Rs 21,753.8 crore (approximately $2.5 billion).

Portea posts Rs 160 Cr revenue in FY25; narrows losses

EntrackrEntrackr · 1d ago
Portea posts Rs 160 Cr revenue in FY25; narrows losses
Medial

Portea, a Bengaluru-based home healthcare services provider, has halved its losses during the fiscal year ended March 2025. The improvement came on the back of steady revenue growth with controlled expenses in the period. Portea’s revenue from operations grew by 15% to Rs 160 crore in FY25 from Rs 139 crore in FY24, according to its consolidated financial statements sourced from the Registrar of Companies (RoC). Portea offers a range of at-home healthcare services such as nursing, physiotherapy, medical equipment rentals, attendant care, lab tests, consultations, and specialised care. Revenue from these services remained the largest contributor, accounting for 59% of operating income, which rose by 16% year-on-year to Rs 95 crore in FY25. Meanwhile, revenue from product sales, including oxygen concentrators, BiPAP machines, and nebulisers, grew 14% to Rs 56 crore in FY25. Looking at the expenses, the employee benefit cost declined by 4.5% to Rs 52.5 crore in FY25. Its consultancy expenses rose 7% to Rs 44 crore. Meanwhile, the cost of materials increased 21% to Rs 52 crore, and expenses rose 25% to Rs 7.5 crore during the fiscal year. Other overheads, including legal and professional charges, and finance costs, added over Rs 30 crore to the total expense. Overall, Portea kept its total expenses flat at Rs 179 crore in FY25. With revenue rising and costs remaining stable, Portea managed to cut its loss by 49% to Rs 19 crore in FY25 from Rs 37 crore in FY24. Its ROCE and EBITDA margins stood at -40.54% and -6.88%, respectively. On a unit basis, Portea spent Rs 1.12 to earn a rupee during the fiscal year, improving from Rs 1.29 in FY24. The company reported cash and bank balances of Rs 1 crore, while its current assets stood at Rs 68 crore as of March 2025. According to TheKredible, Portea has raised nearly $123 million in funding to date, having Accel and Ventureast as its lead investors. It is worth noting that Portea received SEBI’s approval in 2023 to launch a Rs 1,000 crore initial public offering, but the company has since not taken any further steps to move ahead with the listing.

Ather Energy posts Rs 676 Cr revenue in Q4 FY25, narrows losses by 17%

EntrackrEntrackr · 8m ago
Ather Energy posts Rs 676 Cr revenue in Q4 FY25, narrows losses by 17%
Medial

Electric two-wheeler maker Ather Energy has announced its financial results for the fourth quarter of FY25. The company reported a 29% year-on-year jump in its operating revenue compared to Q4 FY24. Ather’s revenue from operations increased by 29% to Rs 676 crore in Q4 FY25, from Rs 523 crore in Q4 FY24, according to its consolidated quarterly report sourced from the National Stock Exchange (NSE). For the full fiscal year (FY25), Ather Energy’s operating revenue increased 29% to Rs 2,255 crore in FY25 from Rs 1,754 crore in FY24. The company’s cost of materials, driven primarily by battery and component procurement, increased by nearly 16% to Rs 564 crore in Q4 FY25 from Rs 488 crore in the same period last year. Employee benefit expenses saw a decline of 29% YoY to Rs 109 crore in Q4 FY25 compared to Rs 154 crore in Q4 FY24. Depreciation and amortization costs rose 18% to Rs 45 crore, while other operational costs jumped nearly 47% to Rs 204 crore. Overall, Ather’s total expenditure grew 13% to Rs 922 crore in Q4 FY25, up from Rs 819 crore in Q4 FY24. For the full financial year ending March 2025, total expenses rose to Rs 3,117 crore as against Rs 2,674 crore in FY24. As a result, the company’s net losses reduced by 17% to Rs 234 crore in Q4 FY25 from Rs 283 crore in Q4 FY24. On a fiscal basis, its net losses came down 23% to Rs 812 crore in FY25 from Rs 1,060 crore in FY24. Ather Energy made its stock market debut on May 6, 2025, listing at Rs 328 per share on the NSE—2.18% above its issue price of Rs 321. However, the stock closed the day at Rs 300. On Monday, it rose 2.8% to trade at Rs 308.7 before market close, bringing its total market capitalization to Rs 11,497 crore ($1.34 billion). Ather's competitor Ola Electric, which saw a nearly 20% decline in operating revenue during Q3 FY25, has yet to file Q4 results.

Exclusive: Unacademy narrows EBITDA losses by 38% in FY25, reports Rs 826 Cr income

EntrackrEntrackr · 3m ago
Exclusive: Unacademy narrows EBITDA losses by 38% in FY25, reports Rs 826 Cr income
Medial

Unacademy’s total revenue decreased 16% year on year to Rs 826.3 crore in FY25, compared to Rs 988 crore in FY24, according to the internal document reviewed by Entrackr. Despite the year-on-year decrease in total revenue, edtech unicorn Unacademy managed to reduce its EBITDA losses by 37.6% year-on-year in the fiscal year ending March 2025. Moreover, the SoftBank-backed firm also reduced its net losses by 31% year-on-year to Rs 436 crore in FY25. The firm’s EBITDA loss was Rs 305 crore, down from Rs 489 crore in FY24, a 38% reduction due to cost optimization measures. As of March 2025, Unacademy had a cash and cash equivalent balance of Rs 1,238 crore. Recently, Unacademy elevated Sumit Jain, co-founder and head of its Graphy subsidiary, as CEO of its flagship Test Prep business.

Cashfree posts Rs 640 Cr revenue in FY25, losses rise 14%

EntrackrEntrackr · 3m ago
Cashfree posts Rs 640 Cr revenue in FY25, losses rise 14%
Medial

Fintrackr All Stories Cashfree posts Rs 640 Cr revenue in FY25, losses rise 14% Cashfree struggled with growth in FY25, even after the Reserve Bank of India removed merchant onboarding restrictions for leading companies. State Bank of India-backed Cashfree is no exception, as the firm’s operating scale remained flat in FY25. Cashfree reported an operating revenue of Rs 640 crore in FY25 against Rs 643 crore in FY24, according to the company’s consolidated financial statements filed with the Registrar of Companies (RoC). Founded in 2015 by Akash Sinha and Reeju Datta, Cashfree provides businesses with a fast and easy way to collect payments online, make payouts, improve conversions, and verify identity and detect fraud during KYC and onboarding. The company claims to enable large businesses to process 12,000 transactions per second during peak demand. The revenue breakup for FY25 shows payment gateway commissions accounted for 75% of the operating revenue at Rs 481 crore. Payout commissions added another Rs 55 crore, while commission income from other services contributed the rest Rs 103 crore. With other income of around Rs 1 crore, the Bengaluru-based company posted a total income of Rs 641 crore in the last fiscal year. On the expense side, payment gateway processing cost accounted for 53% of the total expense, decreasing by 2% to Rs 419 crore in FY25 from Rs 427 crore in FY24. The company’s other key expense items include employee benefits, marketing, and technology investments. Its marketing expenses notably surged 150% to Rs 20 crore in FY25. The firm’s employee benefits costs remained flat at Rs 243 crore in FY25 compared to Rs 245 crore in FY24. Depreciation, finance cost and other overheads added another Rs 80 crore to the rising expenses. In the end, Cashfree’s total costs increased 2% to Rs 795 crore from Rs 779 crore last year. Although top-line performance remained stable, the company’s net loss widened 14% to Rs 154 crore from Rs 135 crore in the previous fiscal. Its EBITDA loss increased to Rs 132 crore, pushing the EBITDA margin down to -20.63% from -17.42% the previous year. In the coming year, Cashfree is expected to reduce its marketing expenses to lower losses and strengthen its financial position in FY26. The ban on real money gaming platforms is also expected to affect the business of payments firms including Cashfree significantly in the ongoing fiscal year. Ahead of FY26, Cashfree raised $53 million in a round led by Krafton, marking its first funding in nearly four years. Overall, the company has raised $95 million from investors including Y Combinator, Smilegate Investments, and the State Bank of India.

Sugar.fit posts 77% revenue growth in FY25, narrows losses

EntrackrEntrackr · 1d ago
Sugar.fit posts 77% revenue growth in FY25, narrows losses
Medial

Fintrackr All Stories Sugar.fit posts 77% revenue growth in FY25, narrows losses Sugar.fit, a digital health and diabetes management startup, reported a sharp growth in its operating revenue in the fiscal year ending March 2025, even as losses narrowed marginally amid rising expenses. Priyanshu Kamal 16 Jan 2026 11:29 IST Sugar.fit’s revenue from operations surged 77% to Rs 66.5 crore in FY25 from Rs 37.5 crore in FY24, according to its financial statements sourced from the Registrar of Companies (RoC). Sugar.fit offers a diabetes care program that combines innovative technology with personalized human interventions. Revenue from services was the sole source of income for the company. Including other income of Rs 8.5 crore, Sugar.fit’s total income stood at Rs 75 crore in FY25 from Rs 42 crore a year earlier. On the spending side, advertising and employee-related costs remained the largest cost centres for the company. Expenses stood flat at Rs 34 crore, accounting for 29% of total expenses, while employee benefit expenses rose 18% to Rs 33 crore, forming 28% of overall costs. Cost of materials consumed jumped sharply to Rs 21 crore in FY25 from Rs 0.6 crore in FY24, contributing nearly 18% of total expenditure. Other overheads, including legal and professional charges and miscellaneous expenses, together added over Rs 24 crore during the year. Overall, total expense rose 31.5% to Rs 117 crore in FY25 from Rs 89 crore in FY24. Sugar.fit reduced its losses by 11% to Rs 42 crore in FY25 from Rs 47 crore in FY24. Its ROCE and EBITDA margin stood at -53.66% and -68.27% respectively. On a unit basis, Sugar.fit spent Rs 1.76 to earn a rupee during FY25, an improvement from Rs 2.37 in FY24. Sugar.fit’s cash and bank balances fell sharply to Rs 1 crore as of March 2025 from Rs 5.6 crore in FY24, while current assets stood at Rs 101 crore. According to TheKredible, Sugar.Fit has raised a total of $26 million of funding till date, having MassMutual Ventures and Tanglin Venture as its lead investors. The numbers might look concerning, but there is a reason Sugar.fit is working at it, and that is the sheer size of the market in India. India is diabetes central on Earth, and the data and learnings for Sugar.fit as it keeps expanding its influence is bound to be of value for the firm as well. On a standalone basis, it remains an uphill climb for the firm, as the market has limited paying capacity considering the vast amount of solutions being sold for every pocket. Certainly a firm where investors need to have a longer horizon in mind.

Healthians posts Rs 263 Cr revenue in FY25; nears breakeven

EntrackrEntrackr · 1m ago
Healthians posts Rs 263 Cr revenue in FY25; nears breakeven
Medial

Healthians posts Rs 263 Cr revenue in FY25; nears breakeven Healthians didn't manage notable growth in the fiscal year ending March 2025. However, the WestBridge-backed company narrowed its losses by 89% year on year and neared break-even during the same period. The firm’s operating revenue increased 8% year-on-year to Rs 263 crore in FY25, up from Rs 243 crore in FY24, as per its consolidated financial statements filed with the Registrar of Companies (RoC). Including non-operating income of Rs 7 crore, the company’s total income grew 7% to Rs 270 crore during the year. Cost optimisation played a key role in supporting the company’s financial recovery. Total expenses declined 8% to Rs 275 crore in FY25, compared to Rs 298 crore last year. Among the major cost heads, employee benefits, the largest expense category, dropped 13% year-on-year to Rs 104 crore in FY25 from Rs 120 crore in FY24. Cost of materials contracted 7% to Rs 54 crore. Advertising costs rose 10% to Rs 43 crore. Meanwhile, depreciation and finance costs remained stable at Rs 29 crore and Rs 15 crore, respectively. The improvement in revenue and control of key expenses helped Healthians bring down its losses sharply by 89% to Rs 5 crore in FY25 from Rs 45 crore in FY24. The firm posted positive EBITDA of Rs 32 crore in FY25 with EBITDA margin of 12.17%. Its ROCE stood at 2.73% in the same period. On a unit basis, the company spent Rs 1.05 to earn a rupee of operating revenue in FY25. The firm’s current assets increased slightly to Rs 170 crore including cash and bank balances worth Rs 49 crore in the fiscal. According to startup data intelligence platform TheKredible, Healthians has raised a total of $75 million of funding till date, having WestBridge, BEENEXT, DG Ventures and Youwecan as its lead investors. The company’s founder and CEO, Deepak Sahni owns 6.5% of the company.

Download the medial app to read full posts, comements and news.